BACKGROUND: NBS1 gene, which product participates in DNA repair, has been postulated to be a susceptibility factor for a number of types of cancer, including breast cancer. The carrier frequency of the 657del5 and I171V NBS1 gene mutations among Polish patients with familial breast and/or ovarian cancer was compared with that of randomly selected newborns. PATIENTS AND METHODS: Using allele-specific amplification-polymerase chain reaction (ASAPCR) and restriction fragment length polymorphismpolymerase chain reaction (RFLP-PCR) techniques, blood samples were analysed from 250 patients with breast or/and ovarian cancer and a total number of 4,000 for 657del5 mutation and 1,300 for I1171V mutation controls. RESULTS: Although an increased frequency of both mutations in cancer cases - 0.8% of 657del5 and 2.4% of I171V, compared to controls - 0.52% and 1.38%, respectively, was found, the differences were not statistically significant. CONCLUSION: Our results indicate that NBS1 mutations do not contribute significantly to breast or ovarian cancer development.
BACKGROUND:NBS1 gene, which product participates in DNA repair, has been postulated to be a susceptibility factor for a number of types of cancer, including breast cancer. The carrier frequency of the 657del5 and I171VNBS1 gene mutations among Polish patients with familial breast and/or ovarian cancer was compared with that of randomly selected newborns. PATIENTS AND METHODS: Using allele-specific amplification-polymerase chain reaction (ASAPCR) and restriction fragment length polymorphismpolymerase chain reaction (RFLP-PCR) techniques, blood samples were analysed from 250 patients with breast or/and ovarian cancer and a total number of 4,000 for 657del5 mutation and 1,300 for I1171V mutation controls. RESULTS: Although an increased frequency of both mutations in cancer cases - 0.8% of 657del5 and 2.4% of I171V, compared to controls - 0.52% and 1.38%, respectively, was found, the differences were not statistically significant. CONCLUSION: Our results indicate that NBS1 mutations do not contribute significantly to breast or ovarian cancer development.
Authors: Haeyoung Kim; Dae-Yeon Cho; Doo Ho Choi; Gee Hue Jung; Inkyung Shin; Won Park; Seung Jae Huh; Sung-Won Kim; Sue K Park; Jong Won Lee; Seok Jin Nam; Jeong Eon Lee; Won Ho Gil; Seok Won Kim Journal: Fam Cancer Date: 2015-09 Impact factor: 2.375
Authors: Timothy R Rebbeck; Nandita Mitra; Susan M Domchek; Fei Wan; Shannon Chuai; Tara M Friebel; Saarene Panossian; Amanda Spurdle; Georgia Chenevix-Trench; Christian F Singer; Georg Pfeiler; Susan L Neuhausen; Henry T Lynch; Judy E Garber; Jeffrey N Weitzel; Claudine Isaacs; Fergus Couch; Steven A Narod; Wendy S Rubinstein; Gail E Tomlinson; Patricia A Ganz; Olufunmilayo I Olopade; Nadine Tung; Joanne L Blum; Roger Greenberg; Katherine L Nathanson; Mary B Daly Journal: Cancer Res Date: 2009-07-07 Impact factor: 12.701
Authors: Eva Seemanova; Raymonda Varon; Jan Vejvalka; Petr Jarolim; Pavel Seeman; Krystyna H Chrzanowska; Martin Digweed; Igor Resnick; Ivo Kremensky; Kathrin Saar; Katrin Hoffmann; Véronique Dutrannoy; Mohsen Karbasiyan; Mehdi Ghani; Ivo Barić; Mustafa Tekin; Peter Kovacs; Michael Krawczak; André Reis; Karl Sperling; Michael Nothnagel Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240
Authors: Joanne Kotsopoulos; Kelly Metcalfe; Jill Alston; Dina Nikitina; Ophira Ginsburg; Andrea Eisen; Rochelle Demsky; Mohammad Akbari; Kevin Zbuk; Steven A Narod Journal: BMC Cancer Date: 2014-03-25 Impact factor: 4.430